ClariTrial — AI Clinical Trial Intelligence

Explore/Alzheimer's disease MCI prevention trials Phase 2 Phase 3

Status

Phase

26 results for “Alzheimer's disease MCI prevention trials Phase 2 Phase 3”

Page 1 of 2

NCT06797817

Not Yet Recruiting

Tributyrin Treatment in Mild Alzheimer Disease: Assessment of Butyrate Effects Via the Gut-Brain

Phase 3Alzheimer Disease (AD)

tributyrinPlacebo

Universidad de Almeria156 participants1 site · SpainCompletes Sep 2026

CT.gov Full analysis →

NCT02191267

Completed

Results posted

Tau Imaging of Chronic Traumatic Encephalopathy

Phase 2Chronic Traumatic Encephalopathy

[F18]-T807[F18]-FlorbetapirMRI/MRS+1 more

Brigham and Women's Hospital30 participants2 sites · United StatesCompletes Sep 2016

CT.gov Full analysis →

NCT05894954

Completed

Precision Medicine Approach for Early Dementia & Mild Cognitive Impairment

Phase 3Mild Cognitive ImpairmentDementia, Mild

Precision Medicine ApproachHormones and Medications tailored to lab tests, combined with devices that support stress management and brain exercisesStandard-of-Care+1 more

Alzheimer's Prevention and Reversal Project, Inc.73 participants6 sites · United StatesCompletes Oct 2025

CT.gov Full analysis →

NCT07392723

Recruiting

ALA-enriched Nutrition for Prevention of Cognitive Decline in APOE4 Older Adults

Phase 2Cognitive DysfunctionAlzheimer DiseaseBlood-Brain Barrier

Alpha-Linolenic Acid (2.6 g/day)Placebo Control Group

Michal Schnaider Beeri, Ph.D.20 participants1 site · United StatesCompletes Apr 2027

CT.gov Full analysis →

NCT02707458

Completed

Dosage and Efficacy of Probucol-induced apoE to Negate Cognitive Deterioration

Phase 1Phase 2Dementia of the Alzheimer TypeAge-related Cognitive DeclineMild Cognitive Impairment Due to Alzheimer Disease

Probucol

Douglas Mental Health University Institute23 participants1 site · CanadaCompletes Mar 2017

CT.gov Full analysis →

NCT01931566

Terminated

Results posted

Biomarker Qualification for Risk of Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease (AD) and Safety and Efficacy Evaluation of Pioglitazone in Delaying Its Onset

Phase 3Mild Cognitive Impairment Due to Alzheimer's Disease

PioglitazonePioglitazone placebo

Takeda3,494 participants55 sites · United States, Australia, GermanyCompletes Jul 2018

CT.gov Full analysis →

NCT01582854

Completed

Results posted

Efficacy and Safety of Actovegin in Post-stroke Cognitive Impairment (PSCI)

Phase 3Post-Stroke Cognitive Impairment (PSCI)

ActoveginPlacebo

Takeda503 participants14 sites · Belarus, Kazakhstan, RussiaCompletes Nov 2014

CT.gov Full analysis →

NCT04871074

Completed

Results posted

The Synapse Project

Phase 2Alzheimer Disease

UCB-JMRI ScanPET Scan

University of Wisconsin, Madison100 participants1 site · United StatesCompletes Oct 2023

CT.gov Full analysis →

NCT01055392

UNKNOWN

Disease-modifying Properties of Lithium in the Neurobiology of Alzheimer's Disease

Phase 2Cognitive ImpairmentAlzheimer Disease

Lithium CarbonatePlacebo

University of Sao Paulo80 participants1 site · BrazilCompletes Mar 2009

CT.gov Full analysis →

NCT04710030

Completed

Valacyclovir for Mild Cognitive Impairment

Phase 2Mild Cognitive ImpairmentHerpes Simplex 1Herpes Simplex 2

Valacyclovir hydrochloride 500mg capletPlacebo sugar pill caplet

New York State Psychiatric Institute50 participants1 site · United StatesCompletes Oct 2024

CT.gov Full analysis →

NCT00620191

Completed

Results posted

Metformin in Amnestic Mild Cognitive Impairment

Phase 2Mild Cognitive Impairment

MetforminPlacebo

Columbia University80 participants1 site · United StatesCompletes Feb 2012

CT.gov Full analysis →

NCT02565511

Terminated

Results posted

A Study of CAD106 and CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease

Phase 2Phase 3Alzheimers Disease

CAD106 ImmunotherapyPlacebo to CAD106CNP520+2 more

Novartis Pharmaceuticals480 participants129 sites · United States, Australia, BelgiumCompletes Apr 2020

CT.gov Full analysis →

NCT02491268

Completed

A Trial of Cilostazol in Patients With Mild Cognitive Impairment (COMCID)

Phase 2Mild Cognitive Impairment

CilostazolPlacebo

National Cerebral and Cardiovascular Center, Japan166 participants1 site · JapanCompletes Aug 2020

CT.gov Full analysis →

NCT03362996

UNKNOWN

Management of Mild Cognitive Impairment Patients With Extra Virgin Olive Oil - MICOIL

Phase 2Mild Cognitive Impairment

Freshly-Pressed Extra Virgin Olive Oilextra virgin olive oilmediterranean diet

Greek Alzheimer's Association and Related Disorders150 participants1 site · GreeceCompletes Feb 2018

CT.gov Full analysis →

NCT01219244

Completed

Effects of Dietary Interventions on the Brain in Mild Cognitive Impairment (MCI)

Phase 2Phase 3Mild Cognitive Impairment

caloric restrictionomega-3 supplementationresveratrol supplementation+3 more

Charite University, Berlin, Germany330 participants1 site · GermanyCompletes Jul 2016

CT.gov Full analysis →

1–15 of 26

Explore/Alzheimer's disease MCI prevention trials Phase 2 Phase 3

Status

Phase

26 results for “Alzheimer's disease MCI prevention trials Phase 2 Phase 3”

Page 1 of 2

NCT06797817

Not Yet Recruiting

Tributyrin Treatment in Mild Alzheimer Disease: Assessment of Butyrate Effects Via the Gut-Brain

Phase 3Alzheimer Disease (AD)

tributyrinPlacebo

Universidad de Almeria156 participants1 site · SpainCompletes Sep 2026

CT.gov Full analysis →

NCT02191267

Completed

Results posted

Tau Imaging of Chronic Traumatic Encephalopathy

Phase 2Chronic Traumatic Encephalopathy

[F18]-T807[F18]-FlorbetapirMRI/MRS+1 more

Brigham and Women's Hospital30 participants2 sites · United StatesCompletes Sep 2016

CT.gov Full analysis →

NCT05894954

Completed

Precision Medicine Approach for Early Dementia & Mild Cognitive Impairment

Phase 3Mild Cognitive ImpairmentDementia, Mild

Precision Medicine ApproachHormones and Medications tailored to lab tests, combined with devices that support stress management and brain exercisesStandard-of-Care+1 more

Alzheimer's Prevention and Reversal Project, Inc.73 participants6 sites · United StatesCompletes Oct 2025

CT.gov Full analysis →

NCT07392723

Recruiting

ALA-enriched Nutrition for Prevention of Cognitive Decline in APOE4 Older Adults

Phase 2Cognitive DysfunctionAlzheimer DiseaseBlood-Brain Barrier

Alpha-Linolenic Acid (2.6 g/day)Placebo Control Group

Michal Schnaider Beeri, Ph.D.20 participants1 site · United StatesCompletes Apr 2027

CT.gov Full analysis →

NCT02707458

Completed

Dosage and Efficacy of Probucol-induced apoE to Negate Cognitive Deterioration

Phase 1Phase 2Dementia of the Alzheimer TypeAge-related Cognitive DeclineMild Cognitive Impairment Due to Alzheimer Disease

Probucol

Douglas Mental Health University Institute23 participants1 site · CanadaCompletes Mar 2017

CT.gov Full analysis →

NCT01931566

Terminated

Results posted

Biomarker Qualification for Risk of Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease (AD) and Safety and Efficacy Evaluation of Pioglitazone in Delaying Its Onset

Phase 3Mild Cognitive Impairment Due to Alzheimer's Disease

PioglitazonePioglitazone placebo

Takeda3,494 participants55 sites · United States, Australia, GermanyCompletes Jul 2018

CT.gov Full analysis →

NCT01582854

Completed

Results posted

Efficacy and Safety of Actovegin in Post-stroke Cognitive Impairment (PSCI)

Phase 3Post-Stroke Cognitive Impairment (PSCI)

ActoveginPlacebo

Takeda503 participants14 sites · Belarus, Kazakhstan, RussiaCompletes Nov 2014

CT.gov Full analysis →

NCT04871074

Completed

Results posted

The Synapse Project

Phase 2Alzheimer Disease

UCB-JMRI ScanPET Scan

University of Wisconsin, Madison100 participants1 site · United StatesCompletes Oct 2023

CT.gov Full analysis →

NCT01055392

UNKNOWN

Disease-modifying Properties of Lithium in the Neurobiology of Alzheimer's Disease

Phase 2Cognitive ImpairmentAlzheimer Disease

Lithium CarbonatePlacebo

University of Sao Paulo80 participants1 site · BrazilCompletes Mar 2009

CT.gov Full analysis →

NCT04710030

Completed

Valacyclovir for Mild Cognitive Impairment

Phase 2Mild Cognitive ImpairmentHerpes Simplex 1Herpes Simplex 2

Valacyclovir hydrochloride 500mg capletPlacebo sugar pill caplet

New York State Psychiatric Institute50 participants1 site · United StatesCompletes Oct 2024

CT.gov Full analysis →

NCT00620191

Completed

Results posted

Metformin in Amnestic Mild Cognitive Impairment

Phase 2Mild Cognitive Impairment

MetforminPlacebo

Columbia University80 participants1 site · United StatesCompletes Feb 2012

CT.gov Full analysis →

NCT02565511

Terminated

Results posted

A Study of CAD106 and CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease

Phase 2Phase 3Alzheimers Disease

CAD106 ImmunotherapyPlacebo to CAD106CNP520+2 more

Novartis Pharmaceuticals480 participants129 sites · United States, Australia, BelgiumCompletes Apr 2020

CT.gov Full analysis →

NCT02491268

Completed

A Trial of Cilostazol in Patients With Mild Cognitive Impairment (COMCID)

Phase 2Mild Cognitive Impairment

CilostazolPlacebo

National Cerebral and Cardiovascular Center, Japan166 participants1 site · JapanCompletes Aug 2020

CT.gov Full analysis →

NCT03362996

UNKNOWN

Management of Mild Cognitive Impairment Patients With Extra Virgin Olive Oil - MICOIL

Phase 2Mild Cognitive Impairment

Freshly-Pressed Extra Virgin Olive Oilextra virgin olive oilmediterranean diet

Greek Alzheimer's Association and Related Disorders150 participants1 site · GreeceCompletes Feb 2018

CT.gov Full analysis →

NCT01219244

Completed

Effects of Dietary Interventions on the Brain in Mild Cognitive Impairment (MCI)

Phase 2Phase 3Mild Cognitive Impairment

caloric restrictionomega-3 supplementationresveratrol supplementation+3 more

Charite University, Berlin, Germany330 participants1 site · GermanyCompletes Jul 2016

CT.gov Full analysis →

1–15 of 26